MoonLake Immunotherapeutics Class A (MLTX)
NASDAQ: MLTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MLTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $942.13M
- EPS (TTM)
- -$3.66
- Dividend yield
- None
- 52-week range
- 9.46 – 23.29
- Day range
- 10.73 – 11.30
- Volume / Avg
- 1.72M / 1.64M
- Beta
- —
- Shares outstanding
- 85.11M
52-week range
MLTX stock today
MoonLake Immunotherapeutics (MLTX) closed at $11.07 on Nov 20, up 0.36% (+$0.04), versus the S&P 500's 3.70% decline. Shares are 52.5% below their 52-week high of $23.29, set on Jun 22, 2026 and 17.0% above the 52-week low of $9.46, near the bottom of the past year's range. MLTX is down 16.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 12.6%.
MoonLake Immunotherapeutics has posted a net loss over the last twelve months (EPS of -$3.66), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About MoonLake Immunotherapeutics
Company profileMoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jorge Santos da Silva Ph.D.
- Headquarters
- Zug
- Employees
- 130
- IPO year
- 2020
- Website
- moonlaketx.com
Financial highlights
Full financialsMoonLake Immunotherapeutics reported a net loss of $227.3 million, compared with a loss of $118.9 million a year earlier. Diluted earnings per share came in at -$3.53.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-227.32M | $-118.94M | $-36.01M | $-49.97M | $-4.54M |
| EPS (diluted) | $-3.53 | $-1.89 | $-0.73 | $-1.70 | $-0.31 |
Analyst forecast
ForecastConsensus (16 analysts)
buy
Avg. price target
$30.29+173.62%
- Strong buy 1
- Buy 11
- Hold 2
- Sell 2
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.93 vs $-0.77
- Surprise
- -20.78%
MLTX news
All MLTX news- MoonLake Immunotherapeutics Consensus Price Target Raised 10.66% to $35.55Nasdaq
- MoonLake Reports Wider Q3 Loss At $79 Mln Following BLA Submission For SonelokimabNasdaqMLTX, BF.A
- MoonLake Immunotherapeutics Reports Third Quarter 2026 Financial Results and BLA SubmissionNasdaq
- MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business UpdateGlobeNewswire
MoonLake Immunotherapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SVRASavara Inc. | 4.26 | -18.23% | $939.86M | vs MLTX |
| CYRXCryoPort Inc. | 19.05 | -2.56% | $964.87M | vs MLTX |
| SPTXSeaport Therapeutics Inc. | 18.05 | -1.47% | $966.23M | vs MLTX |
| AKTSAktis Oncology Inc. | 16.15 | -1.52% | $901.14M | vs MLTX |
| OMEROmeros Corporation | 13.21 | -5.71% | $983.66M | vs MLTX |
| LTGOLatigo Biotherapeutics Inc. | 13.00 | -1.81% | $861.89M | vs MLTX |
| ANROAlto Neuroscience Inc. | 25.37 | -4.30% | $1.02B | vs MLTX |
| MTRIMentari Therapeutics Inc. | 14.70 | -3.57% | $856.94M | vs MLTX |
Indexes, lists and sector
MoonLake Immunotherapeutics stock FAQ
What is MoonLake Immunotherapeutics's stock price today?
MLTX last traded at $11.07 as of Nov 20, 4:00 PM EST, up 0.36% on the day. Prices are delayed at least 15 minutes.
Who is MoonLake Immunotherapeutics's CEO?
Dr. Jorge Santos da Silva Ph.D. is the chief executive officer of MoonLake Immunotherapeutics Class A, which has about 130 employees.
What is the MLTX 52-week high?
The 52-week high for MLTX is $23.29 and the 52-week low is $9.46. The stock is currently 52.5% below its high.